AUY922

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Adenocarcinoma of the Pancreas

Conditions

Adenocarcinoma of the Pancreas, Metastatic Disease

Trial Timeline

Jan 1, 2012 → Aug 1, 2013

NCT ID

NCT01484860

About AUY922

AUY922 is a phase 2 stage product being developed by Novartis for Adenocarcinoma of the Pancreas. The current trial status is terminated. This product is registered under clinical trial identifier NCT01484860. Target conditions include Adenocarcinoma of the Pancreas, Metastatic Disease.

What happened to similar drugs?

1 of 20 similar drugs in Adenocarcinoma of the Pancreas were approved

Approved (1) Terminated (0) Active (19)

✅ApatinibTabletsJiangsu Hengrui MedicineApproved

🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3

🔄CT-P16 + AvastinCelltrionPhase 3

🔄Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3

🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3

🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3

🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01485536	Phase 2	Terminated	Aug 1, 2012	Nov 1, 2015	Lymphoma
NCT01668173	Phase 2	Terminated	Aug 1, 2012	May 1, 2015	Myeloproliferative Neoplasms
NCT01484860	Phase 2	Terminated	Jan 1, 2012	Aug 1, 2013	Adenocarcinoma of the Pancreas
NCT01404650	Phase 2	Completed	Dec 1, 2011	Feb 1, 2015	Gastrointestinal Stromal Tumor
NCT01124864	Phase 2	Completed	Oct 1, 2010	Aug 1, 2014	Non-small-cell Lung Cancer
NCT01132625	Phase 1	Completed	Nov 1, 2008	May 1, 2012	Advanced Solid Tumors

Competing Products

20 competing products in Adenocarcinoma of the Pancreas

See all competitors

Product	Company	Stage	Hype Score
CD40 agonist mitazalimab in combination with chemotherapy	Alligator Bioscience AB	Phase 1/2	26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	18
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	29
ACR-368 + Gemcitabine	Acrivon Therapeutics	Phase 2	32
Ramucirumab	Eli Lilly	Phase 1/2	32
Ramucirumab + Paclitaxel + Placebo	Eli Lilly	Phase 3	40
BA3182	BioAtla	Phase 1	26
Ramucirumab (IMC-1121B ) + Paclitaxel	Eli Lilly	Phase 1	29
CT-P16 + Avastin	Celltrion	Phase 3	40
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracil	Chugai Pharmaceutical	Phase 3	40
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan + Ramucirumab + Paclitaxel	Daiichi Sankyo	Phase 3	44
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	35
DS-8201a	Daiichi Sankyo	Phase 1	29
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO	Daiichi Sankyo	Phase 1/2	39
Enzalutamide	Astellas Pharma	Phase 2	35
zolbetuximab	Astellas Pharma	Pre-clinical	30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	44